On August 12, 2026, in South San Francisco, Allogene Therapeutics, Inc. (Nasdaq: ALLO), a leading clinical-stage biotechnology firm specializing in allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, shared corporate news and disclosed financial outcomes for the quarter concluding on June 30, 2026.